SLXN
Silexion Therapeutics Corp
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.38
▼ 0.02 (5.99%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.41
Prev close
0.40
Day high
0.41
Day low
0.38
Volume
226.97K
Market cap
$2.19M
P/E (TTM)
—
52W range
0.37 – 80.00
Day trading desk
Gap from prior close
+2.48%
Prior close 0.40
VWAP
0.39
-3.54% from price
Relative volume
0.82×
Normal
Session range
9.01%
0.38 – 0.41
Position in range
0%
Near session low
ATR (14D)
0.19
50.63% of price
Prior day high
0.41
PDH
Prior day low
0.38
PDL
Bid / ask spread
—
Quote not published
Session volume
232.29K
Avg 282.47K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.19%
-4.8%
1M
-83.45%
-87.2%
3M
-91.71%
-94.8%
6M
-97.47%
-108.5%
YTD
-97.95%
-110.2%
1Y
-99.42%
-119.4%
3Y
-99.98%
-174.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SLXN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+663.85K
Net buying
Buy transactions
17
686.66K shares
Sell transactions
1
22.82K shares
Net transactions
+18
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
385.99K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 4, 26 | SHIRVAN MITCHELL Officer |
STOCK | 6.00K | $0 | Direct |
| Jun 4, 26 | HADAR ILAN Chief Executive Officer |
STOCK | 10.00K | $0 | Direct |
| Jun 4, 26 | HORENSHTEIN HADAR MIRIT Chief Financial Officer |
STOCK | 7.50K | $0 | Direct |
| Mar 26, 26 | SHIRVAN MITCHELL Officer |
SELL | 22.82K | $31.03K | Direct |
| Feb 20, 26 | SHIRVAN MITCHELL Officer |
STOCK | 49.73K | $0 | Direct |
| Feb 20, 26 | HADAR ILAN Chief Executive Officer |
STOCK | 64.35K | $0 | Direct |
| Feb 20, 26 | ALON RUTH Director |
STOCK | 9.09K | $0 | Direct |
| Feb 20, 26 | HORENSHTEIN HADAR MIRIT Chief Financial Officer |
STOCK | 49.73K | $0 | Direct |
| Feb 20, 26 | LUSHI AVNER Director |
STOCK | 9.09K | $0 | Indirect |
| Feb 20, 26 | ABRAMOV DROR YOSEF Director |
STOCK | 9.09K | $0 | Direct |
| Feb 20, 26 | NOY SHLOMO Director |
STOCK | 9.09K | $0 | Indirect |
| Feb 20, 26 | PELED AMNON PH.D. Director |
STOCK | 7.58K | $0 | Direct |
| Sep 15, 25 | LEVIN ILAN Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 450.00K | $1.80M | Indirect |
| Feb 7, 25 | ALON RUTH Director |
STOCK | 794 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABRAMOV DROR YOSEF |
Director | 10.18K | Stock Award(Grant) |
ALON RUTH |
Director | 10.23K | Stock Award(Grant) |
HADAR ILAN |
Chief Executive Officer | 16.55K | Stock Award(Grant) |
HORENSHTEIN HADAR MIRIT |
Chief Financial Officer | 12.52K | Stock Award(Grant) |
LEVIN ILAN |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
LUSHI AVNER |
Director | — | Stock Award(Grant) |
NOY SHLOMO |
Director | — | Stock Award(Grant) |
PELED AMNON PH.D. |
Director | 8.24K | Stock Award(Grant) |
SHIRVAN MITCHELL |
Officer | 8.79K | Stock Award(Grant) |
Fundamentals
Market cap$2.19M
Enterprise value$1.37M
Revenue (TTM)—
Gross profit—
EBITDA$-14.12M
Net income$-13.96M
EPS (TTM)$-19.89
Free cash flow—
Total cash$2.23M
Total debt$1.41M
Book value / share$0.86
Shares outstanding5.56M
Float5.56M
Short % of float2.41%
Dividend yield—
Beta (5Y)-0.27
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.62
PEG ratio—
Price / sales—
Price / book0.46
EV / revenue—
EV / EBITDA-0.10
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity3,204.55
Current ratio0.94
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $7.14M | $5.82M | $3.71M | $3.23M | +22.8% |
| Selling, general & admin | $4.48M | $6.73M | $928.00K | $577.00K | -33.5% |
| Total operating expense | $11.63M | $12.57M | $4.68M | $3.86M | -7.5% |
| Operating income | -$11.63M | -$12.57M | -$4.68M | -$3.86M | +7.5% |
| Net interest income | $129.00K | -$4.84M | $144.00K | $29.00K | +102.7% |
| Pre-tax income | -$11.91M | -$16.51M | -$5.08M | -$3.46M | +27.9% |
| Tax provision | $3.00K | $10.00K | $32.00K | $24.00K | -70.0% |
| Net income | -$11.91M | -$16.44M | -$4.94M | -$3.21M | +27.6% |
| Net income to common | -$11.91M | -$16.44M | -$4.94M | -$3.21M | +27.6% |
| Basic EPS | -89.60 | -3,949.40 | -818.48 | -532.46 | +97.7% |
| Diluted EPS | -89.60 | -3,949.40 | -818.48 | -532.46 | +97.7% |
| EBIT | -$11.90M | -$16.50M | -$5.07M | -$3.86M | +27.9% |
| EBITDA | -$11.88M | -$16.48M | -$5.03M | -$3.80M | +27.9% |
| Basic shares | 132.95K | 4.16K | 6.04K | 6.04K | +3,093.6% |
| Diluted shares | 132.95K | 4.16K | 6.04K | 6.04K | +3,093.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.99M | $1.19M | $4.59M | $8.26M | +404.7% |
| Cash & short-term investments | $5.99M | $1.19M | $4.59M | $8.26M | +404.7% |
| Total current assets | $6.64M | $2.25M | $4.98M | $8.84M | +195.0% |
| Property, plant & equipment | $437.00K | $560.00K | $247.00K | $464.00K | -22.0% |
| Total assets | $7.21M | $2.86M | $5.26M | $9.33M | +152.0% |
| Total current liabilities | $2.76M | $3.52M | $2.20M | $1.61M | -21.7% |
| Current debt | — | $1.00M | — | — | — |
| Long-term debt | $1.57M | $2.96M | — | — | -47.0% |
| Total debt | $2.04M | $4.49M | $171.00K | $271.00K | -54.7% |
| Total liabilities | $4.61M | $6.85M | $17.31M | $16.41M | -32.7% |
| Retained earnings | -$55.17M | -$43.25M | -$26.81M | -$21.87M | -27.5% |
| Shareholder equity | $2.60M | -$3.99M | -$15.48M | -$10.66M | +165.3% |
| Working capital | $3.88M | -$1.27M | $2.78M | $7.23M | +404.7% |
| Net tangible assets | $2.60M | -$3.99M | -$15.48M | -$10.66M | +165.3% |
| Shares issued | 312.67K | 12.33K | 6.04K | 6.04K | +2,436.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.91M | -$16.52M | -$5.11M | -$3.49M | +27.9% |
| Depreciation & amortisation | $14.00K | $25.00K | $45.00K | $57.00K | -44.0% |
| Stock-based compensation | $134.00K | $5.86M | $130.00K | $125.00K | -97.7% |
| Change in working capital | $601.00K | -$1.58M | $87.00K | $239.00K | +138.0% |
| Operating cash flow | -$10.82M | -$8.40M | -$4.53M | -$3.33M | -28.9% |
| Capital expenditure | -$9.00K | -$22.00K | -$12.00K | -$40.00K | +59.1% |
| Investing cash flow | -$14.00K | -$22.00K | $573.00K | -$524.00K | +36.4% |
| Financing cash flow | $15.64M | $5.10M | $522.00K | $2.75M | +206.4% |
| Free cash flow | -$10.83M | -$8.42M | -$4.54M | -$3.38M | -28.6% |
| End cash position | $6.08M | $1.27M | $4.64M | $8.31M | +378.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $1.37M | $3.38M | $2.16M | $1.02M | $590.00K | — | -59.4% |
| Selling, general & admin | $1.38M | $1.03M | $1.13M | $1.26M | $1.06M | — | +33.9% |
| Total operating expense | $2.75M | $4.41M | $3.29M | $2.28M | $1.65M | — | -37.6% |
| Operating income | -$2.75M | -$4.41M | -$3.29M | -$2.28M | -$1.65M | — | +37.6% |
| Net interest income | $43.00K | $313.00K | $62.00K | $43.00K | -$91.00K | — | -86.3% |
| Pre-tax income | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | — | +38.1% |
| Tax provision | — | $0 | $0 | $3.00K | — | $1.00K | — |
| Net income | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | — | +38.1% |
| Net income to common | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | — | +38.1% |
| Basic EPS | -8.50 | — | -28.80 | 43.20 | -39.00 | — | — |
| Diluted EPS | -8.50 | — | -28.80 | 43.20 | -39.00 | — | — |
| EBIT | -$2.75M | -$4.41M | -$3.26M | -$2.50M | -$1.73M | — | +37.6% |
| EBITDA | -$2.75M | -$4.40M | -$3.25M | -$2.50M | -$1.72M | — | +37.6% |
| Basic shares | 323.04K | — | 113.27K | 57.95K | 45.19K | — | — |
| Diluted shares | 323.04K | — | 113.27K | 57.95K | 45.19K | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.41M | $5.99M | $9.24M | $3.47M | $6.15M | — | -59.7% |
| Cash & short-term investments | $2.41M | $5.99M | $9.24M | $3.47M | $6.15M | — | -59.7% |
| Total current assets | $4.07M | $6.64M | $11.05M | $5.24M | $7.72M | — | -38.8% |
| Property, plant & equipment | $403.00K | $437.00K | $468.00K | $502.00K | $534.00K | — | -7.8% |
| Total assets | $4.60M | $7.21M | $11.61M | $5.80M | $8.31M | — | -36.2% |
| Total current liabilities | $4.06M | $2.76M | $2.79M | $2.15M | $2.40M | — | +47.2% |
| Current debt | $1.55M | — | — | — | — | $1.00M | — |
| Long-term debt | — | $1.57M | $1.54M | $3.19M | $2.99M | $2.96M | — |
| Total debt | $1.99M | $2.04M | $2.02M | $3.70M | $3.48M | — | -2.3% |
| Total liabilities | $4.31M | $4.61M | $4.64M | $5.68M | $5.72M | — | -6.5% |
| Retained earnings | -$57.90M | -$55.17M | -$50.75M | -$47.49M | -$44.99M | — | -5.0% |
| Shareholder equity | $291.00K | $2.60M | $6.98M | $120.00K | $2.59M | — | -88.8% |
| Working capital | $5.00K | $3.88M | $8.27M | $3.09M | $5.33M | — | -99.9% |
| Net tangible assets | $291.00K | $2.60M | $6.98M | $120.00K | $2.59M | — | -88.8% |
| Shares issued | 339.49K | 312.67K | 312.66K | 57.95K | 57.95K | — | +8.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | +38.1% |
| Depreciation & amortisation | $2.00K | $3.00K | $4.00K | $3.00K | $4.00K | -33.3% |
| Stock-based compensation | $345.00K | $38.00K | $38.00K | $37.00K | $21.00K | +807.9% |
| Change in working capital | -$1.26M | $1.30M | $393.00K | -$273.00K | -$824.00K | -196.9% |
| Operating cash flow | -$3.65M | -$3.02M | -$2.84M | -$2.51M | -$2.45M | -20.9% |
| Capital expenditure | — | -$2.00K | — | -$1.00K | -$6.00K | — |
| Investing cash flow | $0 | -$7.00K | $0 | -$1.00K | -$6.00K | +100.0% |
| Financing cash flow | $83.00K | -$221.00K | $8.62M | -$195.00K | $7.43M | +137.6% |
| Free cash flow | -$3.65M | -$3.02M | -$2.84M | -$2.51M | -$2.46M | -20.8% |
| End cash position | $2.50M | $6.08M | $9.32M | $3.54M | $6.23M | -58.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.12 | -5.17 | -143.9% |
| Mar 2026 | -12.90 | -8.50 | +34.1% |
| Dec 2025 | -11.20 | — | — |
| Sep 2025 | -34.00 | -28.80 | +15.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.91 | 1 | $0 | 0.0% |
| Next quarter | -0.71 | 1 | $0 | 0.0% |
| Current year | -4.99 | 1 | $0 | 0.0% |
| Next year | -18.61 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$60.00
High target$60.00
Low target$60.00
Implied upside15895.73%
Analyst count1
ConsensusBUY
Strong buy / Buy0 / 1
Hold1
Sell / Strong sell0 / 0
Held by insiders6.94%
Held by institutions0.58%
Institutions holding10
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.59
-36.58% from price
SMA 20
1.28
-69.13% from price
SMA 50
2.11
-81.31% from price
SMA 100
4.56
-91.78% from price
SMA 200
12.84
-96.93% from price
EMA 12
0.78
-51.82% from price
EMA 26
1.38
-72.80% from price
EMA 50
2.42
-84.51% from price
RSI (14)
19.5
Oversold
MACD (12,26,9)
-0.60
Hist -0.05
ATR (14)
0.19
48.21% of price
Realised vol 30D
289.6%
Annualised
Bollinger upper
2.79
20, 2σ
Bollinger lower
-0.23
20, 2σ
50 / 200 cross
Death
2.11 vs 12.84
Trend bias
Below 200
-96.93%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
3.31
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
289.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-99.5%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.19
48.21% of price
Beta (reported)
-0.27
5Y monthly, from filing
Short interest
Shares short
21.28K
Prior 13.74K
Change vs prior
+54.9%
Shorts adding
% of float
2.41%
Normal
% of shares out
2.00%
Against total outstanding
Days to cover
0.3
Liquid
Float
5.56M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 15, 25 | Litchfield Hills | INITIATED | — | Buy |
| Mar 20, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| Nov 1, 24 | Maxim Group | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateMay 29, 2026
Headlines
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 9d ago
Top Premarket Decliners
MT Newswires · 11d ago
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
GlobeNewswire · 12d ago
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
GlobeNewswire · 19d ago
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
GlobeNewswire · 26d ago
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
GlobeNewswire · 61d ago
Silexion Therapeutics to Attend BIO International Convention 2026
GlobeNewswire · 68d ago
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
GlobeNewswire · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.